Long noncoding RNA LINC01189 is associated with HCV-hepatocellular carcinoma and regulates cancer cell proliferation and chemoresistance through hsa-miR-155-5p.


Journal

Annals of hepatology
ISSN: 1665-2681
Titre abrégé: Ann Hepatol
Pays: Mexico
ID NLM: 101155885

Informations de publication

Date de publication:
Historique:
received: 25 08 2020
revised: 22 09 2020
accepted: 22 09 2020
pubmed: 16 10 2020
medline: 15 12 2021
entrez: 15 10 2020
Statut: ppublish

Résumé

Emerging evidence has demonstrated that long noncoding RNAs (lncRNAs) may be closely associated with Hepatitis C virus (HCV) infection and the development of hepatocellular carcinoma (HCC). In this study, we investigated the expression and functions of a lncRNA, LINC01189, in HCV-associated HCC. LINC01189 expression was measured in HCC tumors, HCV-infected HCC tumors and HCV-infected HCC cells. LINC01189 was overexpressed in HCV-infected HepG2 cells to measure its function on HCV-correlated cancer proliferation. In HCC cell lines of Huh7 and Hep3B, LINC01189 was upregulated to investigate its effects on cancer cell proliferation and 5-FU chemoresistance. The competing endogenous RNA (ceRNA) target of LINC01189, human microRNA-155-5p (hsa-miR-155-5p) was probed by dual-luciferase assay and qRT-PCR. Hsa-miR-155-5p was upregulated in LINC01189-overexpessed Huh7 and Hep3B cells to investigate their epigenetic correlation on HCC development regulation. LINC01189 is downregulated in HCV-infected HCC tumors and cell lines. LINC01189 overexpression inhibited HCC cancer cell proliferation and 5-FU chemoresistance. Hsa-miR-155-5p was confirmed to be a ceRNA target of LINC01189 in HCC. Upregulating hsa-miR-155-5p reversed the LINC01189-mediated inhibition on HCC proliferation and 5-FU chemoresistance. LINC01189 downregulation is associated with HCV infection in HCC, and it has tumor-suppressing effects on HCC development through hsa-miR-155-5p.

Identifiants

pubmed: 33059056
pii: S1665-2681(20)30184-8
doi: 10.1016/j.aohep.2020.09.013
pii:
doi:

Substances chimiques

MIRN155 microRNA, human 0
MicroRNAs 0
RNA, Long Noncoding 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100269

Informations de copyright

Copyright © 2020 Fundación Clínica Médica Sur, A.C. All rights reserved.

Auteurs

Ying Yao (Y)

Clinical laboratory, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054 Shaanxi, China.

Fang Shu (F)

Clinical laboratory, Third Hospital of Xi'an, 710000, Shaanxi, China.

Fang Wang (F)

Anaesthesiology department, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Xiaoqiang Wang (X)

Department of Cancer Biology, City of Hope National Medical Center, Duarte, CA, 91010, USA.

Zhengshe Guo (Z)

Anaesthesiology department, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Haili Wang (H)

Anaesthesiology department, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Lu Li (L)

Anaesthesiology department, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.

Haigang Lv (H)

Anaesthesiology department, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China. Electronic address: doctorlhg@aol.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH